Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 29.04%, near the low end of its 5-year range (0.00%–68.44%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 1.27%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
1.27%
DEBT TO ASSETS RATIO AVG 3Y
29.67%
DEBT TO ASSETS RATIO AVG 5Y
29.04%
DEBT TO ASSETS RATIO AVG 10Y
25.09%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Exicure, Inc.
Market Cap
$7.04M
Debt to Assets Ratio
0.00%
TTM Avg
1.27%
3Y Avg
29.67%
5Y Avg
29.04%
Market Cap
$6.74M
Debt to Assets Ratio
0.54%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.00M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.60M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.57M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.08M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exicure, Inc. (XCUR) | $7.04M | 0.00% | 1.27% | 29.67% | 29.04% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | 0.54% | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.72M | 0.00% | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.00M | 0.11% | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | 0.07% | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.06M | 0.00% | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.57M | 0.00% | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.17% | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.54M | 0.28% | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.12M | 0.02% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
0.56
Interest Coverage
-10117.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.17% |
| 2025-12-31 | 1.25% |
| 2025-09-30 | 2.40% |
| 2025-06-30 | 2.54% |
| 2025-03-31 | 2.99% |
| 2024-12-31 | 39.42% |
| 2024-09-30 | 57.64% |
| 2024-06-30 | 68.44% |
| 2024-03-31 | 60.62% |
| 2023-12-31 | 57.56% |
| 2023-09-30 | 52.77% |
| 2023-06-30 | 39.87% |
| 2023-03-31 | 29.89% |
| 2022-12-31 | 31.32% |
| 2022-09-30 | 25.75% |
| 2022-06-30 | 20.56% |
| 2022-03-31 | 18.46% |
| 2021-12-31 | 22.72% |
| 2021-09-30 | 31.83% |
| 2021-06-30 | 43.70% |
| 2021-03-31 | 37.12% |
| 2020-12-31 | 24.66% |
| 2020-09-30 | 29.52% |
| 2020-06-30 | 0.20% |
| 2020-03-31 | 0.26% |
| 2019-12-31 | 4.61% |
| 2019-09-30 | 7.23% |
| 2019-06-30 | 26.42% |
| 2019-03-31 | 21.31% |
| 2018-12-31 | 17.13% |
| 2018-09-30 | 13.87% |
| 2018-06-30 | 25.35% |
| 2018-03-31 | 20.03% |
| 2017-12-31 | 16.75% |
| 2017-09-30 | 20.58% |
| 2017-06-30 | 51.03% |
| 2016-12-31 | 27.54% |
